The share prices of some of the world’s largest health care companies have rallied a bit today, despite Donald Trump’s announcement yesterday of a tariff of 100% on US imports of branded or patented pharmaceutical products from 1st October. That’s probably because investors were braced for bad news, which could have been worse. But even if tariffs aren’t such a big deal after all for the global health care sector, it faces other headwinds. So its recovery may be slow.
Become a client to read more
This is premium content that requires an active Capital Economics subscription to view.
Already have an account?
You may already have access to this premium content as part of a paid subscription.
Sign in to read the content in full or get details of how you can access it
Register for free
Sign up for a free account to:
- Unlock additional content
- Register for Capital Economics events
- Receive email updates and economist-curated newsletters
- Request a free trial of our services